Teva Gambles Indictment Is Better Than Pleading Guilty To US Price-Fixing Claims

Teva’s market overhang and legal uncertainty intensifies with DOJ charges it conspired to fix generic drug prices. Five other companies have pled guilty and reached deferred prosecution agreements.

Washington DC, USA-June 5, 2018: Robert F Kennedy Department of Justice building entrance "The Place of Justice is a Hallowed Place" engraved in stone above the door
Department of Justice charges Teva with conspiracies to set generic drug prices • Source: Shutterstock

While other generic manufacturers have freed themselves of government allegations of price fixing with guilty pleas, Teva Pharmaceutical Industries Ltd. apparently was unwilling to do so. Unable to reach an alternative arrangement with the US Department of Justice, it has opted to go to court to fight the claims, leaving it with a substantial overhang and uncertainty over its legal liability.

The DOJ announced late on 25 August that it had charged Teva with participating in three conspiracies to fix prices,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Legal & IP

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.